Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder () in Patients with Myelodysplastic Syndromes.
Chin J Integr Med
; 25(6): 409-415, 2019 Jun.
Article
en En
| MEDLINE
| ID: mdl-29619748
ABSTRACT
OBJECTIVES:
To investigate the relationship between gene mutations and response to Compound Qinghuang Powder (, CQHP) in patients with myelodysplastic syndrome (MDS).METHODS:
Forty-three MDS patients were genotyped by ultra-deep targeted sequencing and the clinical data of patients were collected and the relationship between them was analyzed.RESULTS:
Up to 41.86% of patients harbored genet mutations, in most cases with more than one mutation. The most common mutations were in SF3B1, U2AF1, ASXL1, and DNMT3A. After treatment with CQHP, about 88.00% of patients no longer required blood transfusion, or needed half of prior transfusions.CONCLUSIONS:
CQHP is an effective treatment for patients with MDS, especially those with gene mutations in SF3B1, DNMT3A, U2AF1, and/or ASXL1.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Arsénico
/
Arsenicales
/
Síndromes Mielodisplásicos
/
Medicamentos Herbarios Chinos
/
Estudios de Asociación Genética
/
Mutación
Tipo de estudio:
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2019
Tipo del documento:
Article